Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Dasatinib response in AML

Nathali Kaushansky • 1 Jul 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia Dasatinib
Beat AML

Nathali Kaushansky, PhD, Weizmann Institute of Science, Rehovot, Israel, outlines the study which aimed to predict in vitro response to targeted therapies, based on molecular markers, with subsequent validation in leukemic stem cells. Results showed that dasatinib response in acute myeloid leukemia (AML) is correlated with FLT3/ITD, PTN11 mutations. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals